Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of Crelosidenib in healthy adults
NCT06181045Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of crelosidenib in cholangiocarcinoma (CCA), glioma, acute myeloid leukemia (AML) and 1 more (7 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Treatment Emergent Adverse Events and Serious Adverse Events. Started Feb 2021; status: completed.
02
Drugs
crelosidenib
03
Conditions
cholangiocarcinoma (CCA)gliomaacute myeloid leukemia (AML)solid tumor
Beyond the preview
Go deeper on NCT06181045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06181045.